Inferra AI / Company / RXRX
Recursion Pharmaceuticals, Inc..
RXRX · Health Care
Last earnings Aug 5, 2026
AI analysis
Q2 2025 · reported Aug 5, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
Direction: lowered
No guidance located in the held release
“The Company is lowering its cash operating expense guidance for the full year 2026 by $15 million to $375 million based on additional identified operating efficiencies.”
Capital allocation
Recursion believes that the Company s existing cash and cash equivalents will be sufficient to fund the Company s operating expenses and capital expenditures for at least the next 12 months from the issuance date of these financial statements.
Common stockholders are entitled to receive dividends, as may be declared by the Company s Board of Directors.
Event summary
Recursion Pharmaceuticals, Inc.. Q2 2025 results
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
Recursion believes that the Company s existing cash and cash equivalents will be sufficient to fund the Company s operating expenses and capital expenditures for at least the next 12 months from the issuance date of these financial statements.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
Common stockholders are entitled to receive dividends, as may be declared by the Company s Board of Directors.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
As of June 30, 2026 and December 31, 2025, no dividends had been declared.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
Internal Pipeline Updates REC-1245 (RBM39) Recursion provided updates on the biomarker strategy and patient population currently enrolling in the ongoing Phase 1 2 DAHLIA study.
SEC original ↗Recursion Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Update on target patient population Based on early clinical, preclinical, and causal AI modeling data, Recursion selected ovarian cancer as the initial combination dose expansion cohort.
SEC original ↗Recursion Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Additional tumor types and therapies for single-arm expansion cohorts under evaluation.
SEC original ↗Recursion Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Focused on advancing multiple novel target and or compound programs.
SEC original ↗Recursion Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
, Nature Reviews Drug Discovery (2010) 9, 203 214 13 Pipeline Internal Pipeline PIPELINE Pipeline: Advancing 5+ high-potential programs across oncology and rare disease 16 REC-4539 for Small-Cell Lung Cancer (target: LSD1) is on strategic pause.
SEC original ↗Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit)EX-99Aug 5, 2025
Risks & headwinds
Legal Proceedings 31 Item 1A.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
These statements speak only as of the date of this report and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors and elsewhere in this report.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
Legal Matters The Company may, from time to time, be involved in various legal proceedings arising in the normal course of business.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
On June 23, 2023, the landlord filed a lawsuit against the Company (Industry Office SLC, LLC v.
SEC original ↗Recursion Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QAug 5, 2026
Earnings deck slides
0 decks with slide viewRecursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Recursion Pharmaceuticals, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documentsEarnings releases
14 documentsPresentations
9 documents
Transcripts
0 documentsNo transcripts for Recursion Pharmaceuticals, Inc.. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.